[go: up one dir, main page]

CA2005300A1 - Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant - Google Patents

Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant

Info

Publication number
CA2005300A1
CA2005300A1 CA2005300A CA2005300A CA2005300A1 CA 2005300 A1 CA2005300 A1 CA 2005300A1 CA 2005300 A CA2005300 A CA 2005300A CA 2005300 A CA2005300 A CA 2005300A CA 2005300 A1 CA2005300 A1 CA 2005300A1
Authority
CA
Canada
Prior art keywords
idd
dependent diabetes
insulin dependent
early detection
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2005300A
Other languages
English (en)
Other versions
CA2005300C (fr
Inventor
Mark A. Atkinson
Noel K. Maclaren
William Kastern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26962160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2005300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2005300A1 publication Critical patent/CA2005300A1/fr
Application granted granted Critical
Publication of CA2005300C publication Critical patent/CA2005300C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002005300A 1988-12-13 1989-12-12 Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant Expired - Lifetime CA2005300C (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28363388A 1988-12-13 1988-12-13
US283,633 1988-12-13
US42705189A 1989-10-25 1989-10-25
US427,051 1989-10-25

Publications (2)

Publication Number Publication Date
CA2005300A1 true CA2005300A1 (fr) 1990-06-13
CA2005300C CA2005300C (fr) 2000-02-15

Family

ID=26962160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002005300A Expired - Lifetime CA2005300C (fr) 1988-12-13 1989-12-12 Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant

Country Status (8)

Country Link
EP (1) EP0448635B1 (fr)
KR (1) KR910700459A (fr)
AU (1) AU4815890A (fr)
CA (1) CA2005300C (fr)
DE (1) DE68924354T2 (fr)
DK (1) DK112391A (fr)
ES (1) ES2077670T3 (fr)
WO (1) WO1990007117A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762937A (en) * 1988-12-13 1998-06-09 University Of Florida Research Foundation, Inc. Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US5645998A (en) 1988-12-13 1997-07-08 University Of Florida Research Foundation Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
US6001360A (en) * 1988-12-13 1999-12-14 University Of Florida Method and compositions for early detection and treatment of insulin dependent diabetes mellitus
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
DK0543945T3 (da) * 1990-08-17 1997-03-24 Univ Florida Fremgangsmåder og præparater til tidlig påvisning og behandling af insulinafhængig diabetes mellitus
AU8721991A (en) 1990-09-07 1992-03-30 Regents Of The University Of California, The Methods for the diagnosis and treatment of diabetes
US5512447A (en) * 1990-09-07 1996-04-30 The Regents Of The University Of California Methods for the diagnosis and treatment of diabetes
US6682906B1 (en) 1990-09-21 2004-01-27 The Regents Of The University Of California Cloned glutamic acid decarboxylase
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5998366A (en) * 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
AU8864791A (en) * 1990-10-02 1992-04-28 Trigen Incorporated Antibodies and methods for diagnosis and treatment of diabetes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
JPH06508030A (ja) * 1991-05-15 1994-09-14 ザイモジェネティクス,インコーポレイティド ヒトすい島グルタミン酸デカルボキシラーゼ自己抗原のクローニング及び発現
US5407802A (en) * 1991-12-26 1995-04-18 Immulogic Pharmaceutical Corporation Method of accessing the risks of developing type I diabetes
CA2130997A1 (fr) * 1992-02-27 1993-09-02 C. Garrison Fathman Antigene precoce utile pour le diabete auto-immun
WO1993021529A1 (fr) * 1992-04-14 1993-10-28 Duke University Procede de detection de tumeurs contenant des complexes de p53 et de hsp70
US5200318A (en) * 1992-05-13 1993-04-06 Miles Inc. Diagnosis of IDDM with a panel of immunoreagents
DE4237244A1 (de) * 1992-11-04 1994-05-05 Elias Entwicklungslabor Fuer I Verfahren zur Herstellung hochreiner humaner GAD-1- und GAD-2- Proteine
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
IL112094A0 (en) * 1994-12-21 1995-03-15 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US6303325B1 (en) 1998-05-29 2001-10-16 Dade Behring Inc. Method for detecting analytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006968A1 (fr) * 1988-02-03 1989-08-10 Xoma Corporation Utilisation therapeutique d'immunotoxiques anti-cellules t contre des maladies autoimmunes

Also Published As

Publication number Publication date
CA2005300C (fr) 2000-02-15
DE68924354T2 (de) 1996-02-22
KR910700459A (ko) 1991-03-15
ES2077670T3 (es) 1995-12-01
DK112391D0 (da) 1991-06-12
DE68924354D1 (de) 1995-10-26
AU4815890A (en) 1990-07-10
WO1990007117A1 (fr) 1990-06-28
DK112391A (da) 1991-06-12
EP0448635A1 (fr) 1991-10-02
EP0448635B1 (fr) 1995-09-20

Similar Documents

Publication Publication Date Title
CA2005300A1 (fr) Methodes et composes pour la detection precoce et le traitement du diabete insulino-dependant
CA2089742A1 (fr) Methodes et compositions permettant le depistage precoce et le traitement du diabete sucre insulino-dependant
CA2213935A1 (fr) Agent diagnostique pour le diabete
EP0417271A4 (en) Diagnosis and treatment of insulin dependent diabetes mellitus
CA2260769A1 (fr) Procede immunologique de mise en evidence d'anticorps diriges contre la transglutaminase tissulaire (ttg), utilisation de la ttg a des fins de diagnostic et de controle de therapie et agent pharmaceutique oral contenant de la ttg
EP0378924A3 (fr) Détection de maladies ou dysfonctions neurologiques
AU4499685A (en) In vitro detection of gastrointestinal cancer
AU7652194A (en) A method of assaying collagen fragments in body fluids, a test kit and means for carrying out the method and use of the method to diagnose the presence of disorders associated with the metabolism of collagen
EP1221619A3 (fr) Methode de diagnostic d'affections benignes de la prostate
DE69531345D1 (de) Rekombinant pgp3, verfahren zu dessen herstellung, und dessen verwendung in der diagnose und therapie
CA2104225A1 (fr) Methode pour le diagnostic et le traitement des maladies associees aux auto-antigenes de l'acide glutamique-decarboxylase
WO1995005604A3 (fr) Procedes de diagnostic de la maladie d'alzheimer
SE8701905D0 (sv) A method and a kit for the diagnosis of iga nephropathy
EP0230934A3 (fr) Anticorps monoclonal, procédé de mesure de protéine glucosylée utilisant cet anticorps monoclonal, et trousse à cet effet
AU5263190A (en) Method and kit for determining tyrosine-phosphorylating and dephosphorylating activities
RU2009509C1 (ru) Способ прогнозирования течения псориаза
CA2334864A1 (fr) Compose de reference destine a etre utilise dans l'analyse de lots de levosimendan
AU4484593A (en) Method for the determination of lupus anticoagulant antibodies that cause thrombosis
Gabrieli et al. A clinical study of serum glutamic oxalacetic transaminase isoenzymes in liver diseases
IL108587A0 (en) Methods and kit for the diagnosis of diabetes and prediabetic conditions
AU1673892A (en) Process for diagnosing non-insulin-dependent diabetes mellitus
RU1812489C (ru) Способ диагностики впервые возникшей стенокардии с нестабильным течением
SU1622821A1 (ru) Способ определени активности каталазы в плазме крови
SU1658095A1 (ru) Способ диагностики атеросклероза сосудов головного мозга
AU7692987A (en) Reagent kit, its use and diagnostic process for the detection of hpasp(human pancreatic specific protein)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry